Skip to main content
Premium Trial:

Request an Annual Quote

Something Superior?

Premium

A new study published in Lancet Oncology says that the breast cancer drug letrozole reduces breast cancer recurrence rates and improves survival rates better than tamoxifen, reports The New York Times' Anahad O'Connor. The study involved 8,010 postmenopausal ER+ breast cancer patients who were randomly assigned to receive either letrozole — sold by Novartis under the brand name Femara — or tamoxifen for five years, or both drugs taken in sequence, letrozole for two years followed by tamoxifen for three or vice versa. After a follow-up of about eight years, the researchers found that women given letrozole after surgery had a 20 percent lower risk of breast cancer recurrence and were 21 percent less likely to die from cancer, compared with tamoxifen, O'Connor says. The combination treatment did not significantly lower likelihood of recurrence or death, she adds.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.